Mumbai-based Unichem Laboratories Ltd announced that its Kolhapur active pharmaceutical ingredients (API) manufacturing facility has successfully cleared the US Food and Drug Administration (USFDA) inspection. According to the latest exchange filing, the inspection was carried out between January 27 and February 2, 2026, and was closed with five observations. The company clarified that all observations relate to procedural aspects and are not linked to data integrity concerns. The disclosure was submitted to both NSE and BSE on February 2, 2026, under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
As reported in the latest exchange filing, Unichem stated it will submit its response to the USFDA within the stipulated 15-day timeframe. The company's shares closed at ₹374.65 on the BSE, up 0.16% from the day's opening price, with the stock showing positive movement during market hours following the regulatory disclosure. The filing was signed by the Head – Legal and Company Secretary and was made for information and record purposes, with no financial estimates or forward-looking statements included.
According to the latest financial results, Unichem Laboratories reported strong quarterly performance with consolidated net profit jumping 83.9% to ₹45.30 crore in Q2 FY26 compared to the same period last year. The company's net sales increased 14.1% to ₹578.96 crore in Q2 FY26 over Q2 FY25, demonstrating robust revenue growth. This performance comes after the company's Q3 FY25 results showed a 20.5% year-on-year decline in net profit at ₹58 crore despite revenue rising 14.5% to ₹533 crore.
According to the exchange filing reported by CNBC TV18, the company reported a 20.5% year-on-year decline in net profit for the December quarter at ₹58 crore, compared with ₹73 crore in the same period last year. However, revenue rose 14.5% year-on-year to ₹533 crore from ₹466 crore in Q3FY24. The company's EBITDA more than doubled to ₹85.2 crore from ₹31.6 crore a year ago, with EBITDA margins expanding significantly to 16% in the December quarter, compared with 7% in the corresponding period last year.
